BIOHAVEN PHARMACTL HLDG CO L's ticker is BHVN and the CUSIP is G11196105. A total of 133 filers reported holding BIOHAVEN PHARMACTL HLDG CO L in Q4 2018. The put-call ratio across all filers is 0.63 and the average weighting 1.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2022 | $12,181,000 | +20.6% | 83,600 | -1.9% | 0.04% | +29.6% |
Q1 2022 | $10,102,000 | +53.4% | 85,200 | +78.2% | 0.03% | +68.8% |
Q4 2021 | $6,587,000 | +21.9% | 47,800 | +22.9% | 0.02% | +14.3% |
Q3 2021 | $5,404,000 | +223.6% | 38,900 | +59.2% | 0.01% | +180.0% |
Q1 2021 | $1,670,000 | -74.7% | 24,430 | -68.3% | 0.01% | -72.2% |
Q4 2020 | $6,611,000 | -27.5% | 77,130 | -45.0% | 0.02% | -30.8% |
Q3 2020 | $9,116,000 | +6.9% | 140,230 | +20.2% | 0.03% | +4.0% |
Q2 2020 | $8,527,000 | +49.0% | 116,630 | -30.6% | 0.02% | +13.6% |
Q1 2020 | $5,721,000 | -65.5% | 168,130 | -44.7% | 0.02% | -42.1% |
Q4 2019 | $16,562,000 | +52.1% | 304,230 | +16.5% | 0.04% | +40.7% |
Q3 2019 | $10,890,000 | +30.2% | 261,030 | +36.7% | 0.03% | +28.6% |
Q2 2019 | $8,361,000 | +59.8% | 190,930 | +87.9% | 0.02% | +61.5% |
Q1 2019 | $5,231,000 | +741.0% | 101,630 | +503.9% | 0.01% | +550.0% |
Q4 2018 | $622,000 | – | 16,830 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
RP Management, LLC | 1,111,111 | $154,344,000 | 72.03% |
Knoll Capital Management, LLC | 856,844 | $119,024,000 | 59.36% |
ORACLE INVESTMENT MANAGEMENT INC | 2,124,055 | $295,053,000 | 36.73% |
ARS Investment Partners, LLC | 466,668 | $64,825,000 | 6.49% |
KINGDON CAPITAL MANAGEMENT, L.L.C. | 365,373 | $50,754,000 | 6.18% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 176,400 | $24,490,000 | 5.91% |
SILVERARC CAPITAL MANAGEMENT, LLC | 61,897 | $8,598,000 | 4.86% |
DAFNA Capital Management LLC | 88,100 | $12,238,000 | 3.25% |
Avidity Partners Management LP | 934,200 | $129,770,000 | 2.88% |
Eventide Asset Management | 1,325,000 | $184,056,000 | 2.43% |